AI
MCRB icon

Auour Investments’s Seres Therapeutics MCRB Stock Holding History

Auour Investments’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-850
Closed -$13.1K – 85
2024
Q3 		$13.1K Hold
850
– – ﹤0.01% 79
2024
Q2 		$12.3K Hold
850
– – ﹤0.01% 78
2024
Q1 		$13.2K Hold
850
– – ﹤0.01% 80
2023
Q4 		$20.6K Hold
850
– – 0.01% 73
2023
Q3 		$25.1K Hold
850
– – 0.01% 71
2023
Q2 		$81.4K Buy
+850
New +$92.5K 0.03% 71

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Auour Investments's MCRB Position: Q4 2024 in Review

Auour Investments sold out of Seres Therapeutics (MCRB) in Q4 2024, closing a stake of 850 shares — an estimated $13.1K sold.

Auour Investments first reported a position in MCRB in Q2 2023 and held it in 6 quarters. The position peaked at $81.4K in Q2 2023. 69 funds tracked by Wall St. Rank hold MCRB as of Q4 2024.

  • Auour Investments reported no remaining Seres Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Auour Investments sold 850 Seres Therapeutics shares in Q4 2024, an estimated $13.1K.
  • Auour Investments first reported a position in Seres Therapeutics in Q2 2023 and held it in 6 quarters.
  • Auour Investments's Seres Therapeutics position peaked at $81.4K in Q2 2023.
  • 69 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2024.

Based on Auour Investments's 13F filing for Q4 2024, filed 3 Feb 2025.